What is RxGenomix?
RxGenomix is at the forefront of personalized medicine, offering its ExactMeds pharmacogenomic service. This innovative platform provides tailored medication recommendations by analyzing an individual's unique genetic makeup. The company caters to a broad spectrum of clients, including individuals managing chronic conditions, healthcare providers seeking to improve patient treatment efficacy, and employers aiming to enhance workforce health and reduce healthcare expenditures. RxGenomix's comprehensive suite of services encompasses individual genetic testing, population-level analytics, seamless integration into clinical practices, and robust enterprise solutions designed to refine medication prescribing protocols. By harnessing advanced genetic insights, RxGenomix is dedicated to minimizing adverse drug reactions and elevating the overall efficiency of healthcare delivery.
How much funding has RxGenomix raised?
RxGenomix has raised a total of $318K across 2 funding rounds:
Debt
$150K
Debt
$168K
Debt (2020): $150K with participation from PPP
Debt (2021): $168K led by PPP
What's next for RxGenomix?
With its recent major strategic investment, RxGenomix is well-positioned for significant expansion and further development of its personalized healthcare technologies. The substantial capital infusion, totaling $318K, indicates a late-stage growth phase, likely enabling the company to scale its operations, enhance its ExactMeds platform, and broaden its market reach. Future strategic initiatives may involve forging new partnerships within the healthcare ecosystem, expanding its service offerings to address a wider range of therapeutic areas, and investing in further research and development to solidify its leadership in pharmacogenomics. This latest backing signals strong investor confidence in RxGenomix's mission to revolutionize medication management through genetic insights.
See full RxGenomix company page
